- Market Capitalization, $K 108,080,760
- Shares Outstanding, K 2,692,595
- Annual Sales, $ 43,783 M
- Annual Income, $ 7,382 M
- 60-Month Beta 0.70
- Price/Sales 2.47
- Price/Cash Flow 10.36
- Price/Book 3.67
|Period||Period Low||Period High||Performance|
| || |
+0.32 (+0.80%)since 06/30/21
| || |
+2.80 (+7.50%)since 04/30/21
| || |
-0.11 (-0.27%)since 07/30/20
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients...
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
We believe dividend-paying companies with stable fundamentals are prominent bets now considering the market’s high volatility. So, established dividend stocks AT&T Inc. (T), Vale S.A (VALE), and GlaxoSmithKline...
BRENTFORD, Britain (AP) _ GlaxoSmithKline PLC (GSK) on Wednesday reported second-quarter earnings of $1.95 billion.
|Glaxosmithkline Plc ADR|
|Vaneck Pharmaceutical ETF|
|Pacer Biothreat Strategy ETF|
|Alps Hillman Active Value ETF|
|Pacer Global Cash Cows Dividend ETF|
|Pacer Military Times Best Employers ETF|
|3rd Resistance Point||40.46|
|2nd Resistance Point||40.31|
|1st Resistance Point||40.23|
|1st Support Level||40.00|
|2nd Support Level||39.85|
|3rd Support Level||39.77|